

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 053466/0277		SERIAL NO. Unassigned	
INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>				APPLICANT Jun FUJITA			
				FILING DATE 3/31/2000		GROUP ART UNIT Unassigned	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
✓	A1	9-75085	03/1997	Japan			Abstr.
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
<i>NAD</i>	A2	*Willardson, et al. "Localization of the Ankyrin-binding Site of Erythrocyte Membrane Protein, Band 3," J. Biol. Chem., Vol. 264, No. 27, pp. 15893-15899 (1989)					
<i>NAD</i>	A3	*DeCaprio, et al., "The Product of the Retinoblastoma Susceptibility Gene Has Properties of a Cell Cycle Regulatory Element," Cell, Vol. 58, No. 6 pp. 1085-1095 (1989)					
<i>NAD</i>	A4	*Baeuerle, et al. "Activation of DNA-Binding Activity in an Apparently cytoplasmic Precursor of the NF-K B Transcription Factor," Cell, Vol. 53, No. 2, pp 211-217 (1988)					
EXAMINER <i>NAD</i>				DATE CONSIDERED 8-31-01			
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.							

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 053466/0277	SERIAL NO. 09/509,775
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANT Jun FUJITA	
		FILING DATE 03/31/2000	GROUP ART UNIT 1643

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
01PE							

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
						YES	NO
A1	9-075085	03/97	JAPAN				Abstract

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

NM ✓	A2	*FURUTANI et al.; "Decreased Expression and Rare Somatic Mutation of the CIP1/WAF1 Gene in Human Hepatocellular Carcinoma"; Cancer Letters; 1997; pp. 191-197.
	A3	*WILLARDSON et al.; "Localization of the Ankyrin-binding Site on Erythrocyte Membrane Protein; Brand 3"; The Journal of Biological Chemistry; Vol. 264, No. 27; September 25, 1989; pp. 15893-15899.
	A4	*DECAPRIO et al.; "The Product of the Retinoblastoma Susceptibility Gene Has Properties of A Cell Cycle Regulatory Element"; Cell; Vol. 58; September 22, 1989; pp. 1085-1095.
	A5	*BAEUEERLE et al.; "Activation of DNA-Binding Activity In An Apparently Cytoplasmic Precursor of the NF-κB Transcription Factor"; Cell; Vol. 53; April 22, 1988; pp. 211-217.
	A6	*TOBE et al.; "Prime Liver Cancer in Japan"; 1992; pp. 445-453.
	A7	*TOBE et al.; "Prime Liver Cancer in Japan"; 1992; pp. 243-255.
	A8	*FURUTANI et al.; "Kan-1 (Bile Acid CoA:Amino Acid N-Acyltransferase) Messenger RNA as a Novel Predictive Indicator for Prognosis of Hepatocellular Carcinoma Patients After Partial Hepatectomy"; Hepatology; Vol. 24, No. 6; 1996; pp. 1441-1445.
	A9	*TOBE et al.; "Prime Liver Cancer in Japan"; 1990; pp. 277-287.
	A10	*BELGHITI et al.; "Intrahepatic Recurrence After Resection of Hepatocellular Carcinoma Complicating Cirrhosis"; Ann. Surg.; Vol. 214, No. 2; August 1991; pp. 114-117.
	A11	*MISE et al.; "Clinical Significance of Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor Gene Expression in Liver Tumor"; Hepatology; Vol. 23, No. 3; March 1996; pp. 455-464.
	A12	*CALVET et al.; "Prognostic Factor of Hepatocellular Carcinoma in the West: A Multivariate Analysis in 206 Patients"; Hepatology; Vol. 12, No. 4; 1990; pp. 753-760.
	A13	*FRANCO et al.; "Resection of Hepatocellular Carcinomas"; Gastroenterology; Vol. 98, No. 3; 1990; pp. 733-738
	A14	*TOBE et al.; Predictive Factors for Long Term Prognosis After Partial Hepatectomy for Patients With Hepatocellular Carcinoma in Japan"; Cancer; Vol. 74, No. 10; 1994; pp. 2772-2775.

EXAMINER

N. J. J. J. J.

DATE CONSIDERED

8/29/01

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.